Sulforaphane Ameliorates Nonalcoholic Fatty Liver Disease Induced by High-Fat and High-Fructose Diet via LPS/TLR4 in the Gut–Liver Axis
Nutrients · 01.02.2023 · 15 (3) · 743
DOI: 10.3390/nu15030743 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, online erschienen am 01.02.2023. Verfasst von Ye Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Precision Nutrition and Food Quality, Key Laboratory of Functional Dairy, Ministry of Education, College of Food Science and Nutrit…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2115 Talent Development Program of China Agricultural University.
Abstract (Originalsprache)
The gut–liver axis has emerged as a key player in the progression of non-alcoholic fatty liver disease (NAFLD). Sulforaphane (SFN) is a bioactive compound found in cruciferous vegetables; however, it has not been reported whether SFN improves NAFLD via the gut–liver axis. C57BL/6 mice were fed a high-fat and high-fructose (HFHFr) diet, with or without SFN gavage at doses of 15 and 30 mg·kg−1 body weight for 12 weeks. The results showed that SFN reduced weight gain, hepatic inflammation, and steatosis in HFHFr mice. SFN altered the composition of gut microbes. Moreover, SFN enhanced the intestinal tight junction protein ZO-1, reduced serum LPS, and inhibited LPS/TLR4 and ERS pathways to reduce intestinal inflammation. As a result, SFN protected the intestinal integrity and declined the gut-derived LPS translocations to the liver in HFHFr diet-induced mice. SFN decreased the liver LPS levels and inhibited the LPS/TLR4 pathway activations, thus inhibiting the pro-inflammatory cytokines. Notably, Spearman correlation analysis showed that the protective effect of SFN on intestinal barrier integrity and its anti-inflammatory effect on the liver was associated with improved intestinal dysbiosis. Above all, dietary intervention with SFN attenuates NAFLD through the gut–liver axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Precision Nutrition and Food Quality, Key Laboratory of Functional Dairy, Ministry of Education, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, Chin…
- Henan Shuanghui Investment and Development Co., Ltd., Luohe 462000, China.
- Key Laboratory of Safety Assessment of Genetically Modified Organism (Food Safety), The Ministry of Agriculture and Rural Affairs of the P.R. China, Beijing 100083, China.
ORCID-Profile: Xiaoyun He
Förderung
- 2115 Talent Development Program of China Agricultural University
Zitieren
APA
Xu, Y., Huang, X., Huangfu, B., Hu, Y., Xu, J., Gao, R., Huang, K., & He, X. (2023). Sulforaphane Ameliorates Nonalcoholic Fatty Liver Disease Induced by High-Fat and High-Fructose Diet via LPS/TLR4 in the Gut–Liver Axis. Nutrients, 15(3), 743. https://doi.org/10.3390/nu15030743
Vancouver
Xu Y, Huang X, Huangfu B, Hu Y, Xu J, Gao R, et al. Sulforaphane Ameliorates Nonalcoholic Fatty Liver Disease Induced by High-Fat and High-Fructose Diet via LPS/TLR4 in the Gut–Liver Axis. Nutrients. 2023;15(3):743. doi:10.3390/nu15030743
BibTeX
@article{Xu2023,
author = {Xu, Ye and Huang, Xianghui and Huangfu, Bingxin and Hu, Yanzhou and Xu, Jia and Gao, Ruxin and Huang, Kunlun and He, Xiaoyun},
title = {Sulforaphane Ameliorates Nonalcoholic Fatty Liver Disease Induced by High-Fat and High-Fructose Diet via LPS/TLR4 in the Gut–Liver Axis},
journal = {Nutrients},
year = {2023},
volume = {15},
number = {3},
pages = {743},
doi = {10.3390/nu15030743}
}
EUVIMED